Jane S. Ricciuti, RPh, MS

Disclosures

January 29, 2004

In This Article

Pulmonology Agents

Advair Diskus
(fluticasone propionate/salmeterol) Inhalation Powder

Manufacturer: Glaxo SmithKline

Drug Approval Classification: Supplemental New Drug Application (Approval Date: 11/17/03)

New Indication: This supplemental new drug application for Advair Diskus (fluticasone propionate/salmeterol) Inhalation Powder is for its use in patients with chronic obstructive pulmonary disease associated with chronic bronchitis.

Advair Diskus (fluticasone propionate/salmeterol) Inhalation Powder

Medscape DrugInfo

Advair Diskus (fluticasone propionate/salmeterol) Inhalation Powder

processing....